Yoshihara, Fumiki
,
Imazu, Miki
Hamasaki, Toshimitsu
Anzai, Toshihisa
Yasuda, Satoshi
Ito, Shin
Yamamoto, Haruko
Hashimura, Kazuhiko
Yasumura, Yoshio
Mori, Kiyoshi
Watanabe, Masataka
Asakura, Masanori
Kitakaze, Masafumi
Funding for this research was provided by:
This study was financially sponsored by AstraZeneca Plc. and Ono Pharmaceutical Co., LTD.
Article History
First Online: 28 March 2018
Compliance with Ethical Standards
:
: FY and MK report grants and personal fees from AstraZeneca Plc. and Ono Pharmaceutical Co., LTD, during the conduct of the study.FY also receive grants from the Japanese government (KAKENHI-PROJECT-17K09002), personal fees from Otsuka, personal fees from Chugai, personal fees from Kyowa-Hakko-Kirin, personal fees from Pfizer, personal fees from Boehringer Ingelheim, personal fees from Novo Nordisk, personal fees from Daiichi Sankyo, personal fees from Takeda, personal fees from AstraZeneca, personal fees from Sumitomo Dainippon, outside the submitted work.MK also receive grants from the Japanese government (KAKENHI-PROJECT-15H04826), grants from Japan Heart Foundation, grants from Japan Cardiovascular Research Foundation, grants and personal fees from Asteras, grants and personal fees from Sanofi, personal fees from Daiichi Sankyo, grants and personal fees from Pfizer, grants and personal fees from Ono, personal fees from Bayer, grants from Novartis, personal fees from Bheringer, grants and personal fees from Tanabe-mitsubishi, personal fees from Kowa, personal fees from Dainihon-sumitomo, personal fees from Sawai, personal fees from MSD, grants and personal fees from Otsuka, grants from Nihon Kohden, personal fees from Shionogi, grants and personal fees from Astrazeneca, grants and personal fees from Takeda, from Taisho-toyama, outside the submitted work.MI has nothing to disclose.TH has nothing to disclose.TA has nothing to disclose.SY has nothing to disclose.SI has nothing to disclose.HY has nothing to disclose.KH has nothing to disclose.YY has nothing to disclose.KM reports grants from Mitsubishi Tanabe Pharma Corporation, grants and personal fees from Abbott Japan, outside the submitted work.MW has nothing to disclose.MA reports grants from Acterion Pharmaceutical Japan, grants from Boehringer Ingelheim Japan, Inc., personal fees from Otsuka Pharmaceutical Co., Ltd., personal fees from Sanofi K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from MSD K.K., personal fees from Takeda Pharmaceutical Company Limited., personal fees from Pfizer Japan Inc., outside the submitted work.
: The final protocol was approved by the National Cerebral and Cardiovascular Center Ethics Committee (approval ID M28-059) and each Institutional Review Board of all participating centers and patient enrollment began in April 2017. This study complies with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent will be obtained from all patients before recruitment. Personal information about potential and enrolled participants will remain confidential and data will be never identified using participant’s number. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000025102 (ExternalRef removed).